lobbying_activities: 2773031

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2773031	0dcdcb6e-2524-49dd-acc9-6c7c33fa141b	Q1	KOUNTOUPES DENHAM CARR & REID, LLC	320918	GLENMARK PHARMACEUTICALS, INC., USA	2022	first_quarter	PHA	Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act.	HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2022-04-13T15:08:40-04:00